Drug Trial Radar · NCT01704716
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,569
Actual
Start
Feb 1, 2002
Primary completion
Jan 30, 2025
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- St. Anna KinderkrebsforschungAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 month, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis).The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba ® without s.c. aldesleukin (IL-2)). Last randomisation question (R4) was closed in March 2018. Since then all HRNBL1 patients are being registered and treated according SIOPEN standard recommendation as defined in protocol v1.8. For these patients the use of ch14.18/CHO antibody is recommended without scIL-2 as continuous infusion as standard of care outside of controlled trials. ch14.18/CHO received marketing authorization by EMA in May 2017 (Qarziba ®).In the induction phase, all patients receive Rapid COJEC following the result of the R3 randomization which was closed on June 8th, 2017 after inclusion of 630 patients as planned. Following induction treatment peripheral blood stem cell harvest (PBSCH) is performed and complete excision of the primary tumour will be attempted. Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles. After Rapid COJEC induction, localized patients will proceed to consolidation. Patients aged 12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and surgery to the primary tumour.Consolidation consists of BuMel MAT based on the results of the R1 randomization followed by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary tumour. With amendment 1.9 the End of recruitment was prolonged to Q2 2023 followed by a 5-year patient follow-up period.
Conditions
- Neuroblastoma
Interventions
VincristineDrug
given during Rapid COJEC and modified N7 therapy
AldesleukinDrug
Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
ch14.18/CHODrug
ch14.18/CHO antibody is given during MRD treatment
CarboplatinDrug
Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
EtoposideDrug
Etoposide is given during Induction Treatment (both R3 randomisation arms)
CisplatinDrug
Cisplatin is given during Induction Treatment (both R3 randomisation arms)
CyclophosphamideDrug
Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
DoxorubicinDrug
Doxorubicin is given during Induction Treatment (R3 arm modified N7)
G-CSFDrug
G-CSF is given during Induction Treatment
BusulfanDrug
In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
MelphalanDrug
Melphalan is given during MAT treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event Free Survival (R1: MAT therapy)Time frame: Up to three years
- Event Free Survival (immunotherapy)Time frame: Up to three years
- Complete metastatic response (R3: Induction therapy)Time frame: Up to 95 days
- Event free survival (R3: Induction therapy)Time frame: Up to three years
Locations
122 sites in 20 countries. Site status is shown where the registry gives one.
The John Hunter Children's Hospital
Newcastle, Australia
Sydney Children's Hospital
Sydney, Australia
Univ.-Klinik für Kinder- und Jugendheilkunde Graz
Graz, Austria
Univ.Klinik f. Kinder-u. Jugendheilkunde Innsbruck
Innsbruck, Austria
Landes- Kinderklinik Linz
Linz, Austria
St. Johanns Spital LKH Salzburg
Salzburg, Austria
St. Anna Kinderspital
Vienna, Austra, Austria
Cliniques universitaires St-Luc
Brussels, Belgium
Hôpital des Enfants
Brussels, Belgium
University Hospital Gent
Ghent, Belgium
UZ Gasthuisberg
Leuven, Belgium
CHR Citadelle
Liège, Belgium
Clinique de l'Espérance
Montegnée, Belgium
University Hospital Motol
Prague, Czechia
Aarhus Universitetshospital
Aarhus, Denmark
National State Hospital
Copenhagen, Denmark
University Hospital of Odense
Odense, Denmark
Skejby Hospital
Skejby, Denmark
Hopital d'Enfants Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHR Pellegrin
Le Pellerin, France
Centre Oscar Lambret de Lille
Lille, France
Hopitaux de Marseille La Timone
Marseille, France
CHR de Nantes
Nantes, France
Hôpital Trousseau Paris
Paris, France
Institut Curie
Paris, France
Hôpital American Memorial Hospital
Reims, France
CHU-Saint Etienne
Saint-Etienne, France
Hôpital de Hautepierre
Strasbourg, France
Hôpital D'Enfants de Toulouse
Toulouse, France
Institut Gustave Roussy
Villejuif, France
"A&P Kyriakou" Children's Hospital
Athens, Greece
Aghia Sophia Children's Hospital
Athens, Greece
MITERA Hospital
Heraklion, Greece
PEPAGNH University Hospital
Heraklion, Greece
Madarász Children Hospital Budapest
Budapest, Hungary
Semmelweis University of Budapest
Budapest, Hungary
University of Debrecen
Debrecen, Hungary
University of Pecs
Pécs, Hungary
University of Szeged
Szeged, Hungary
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.